The pathologic and genomic evolution of primary malignant phyllodes tumors of the breast: retrospective cohort study and case-control genomic analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Fibroadenoma-like areas in malignant phyllodes tumors of the breast do not significantly predict recurrence. Mediator of RNA polymerase II transcription subunit 12 homolog mutations (MED12m) also showed no association with recurrence or these areas.
Area Of Science
- Oncology
- Pathology
- Genetics
Background
- Malignant phyllodes tumors of the breast (B-MPT) require accurate prognostication.
- Mediator of RNA polymerase II transcription subunit 12 homolog mutations (MED12m) and prior fibroadenoma history may influence outcomes.
- Fibroadenoma-like areas (FLA) are hypothesized to indicate a pre-existing fibroadenoma.
Purpose Of The Study
- To evaluate the prognostic significance of FLA in resected primary B-MPTs.
- To assess the association between MED12m and cancer recurrences.
- To determine if FLA and MED12m can aid in B-MPT prognostication.
Main Methods
- Retrospective cohort study of 89 patients with non-metastatic B-MPT undergoing surgery (2000-2021).
- Pathological review by 3 pathologists to identify FLA.
- Nested case-control genomic analysis for MED12m association with FLA and recurrences.
Main Results
- 47% of B-MPTs exhibited FLA.
- FLA were not significantly associated with local recurrence (5-year cumulative incidence: 13.0% vs 23.6%) or distant recurrence (5-year cumulative incidence: 12.5% vs 8.9%).
- MED12m showed no association with distant recurrences or the presence of FLA.
Conclusions
- FLA are common in B-MPTs but do not significantly correlate with reduced local or distant recurrence rates.
- MED12m is not associated with recurrence or FLA in this cohort.
- FLA and MED12m do not appear to be significant prognostic markers for B-MPT recurrence.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...